Education
About Us
Working with TipRanks
Follow Us
Idorsia Ltd (CH:IDIA)
:IDIA
IDIA Stock Chart & Stats
CHF3.15
-CHF0.05(-3.98%)
At close: 4:00 PM EST
CHF3.15
-CHF0.05(-3.98%)
Day’s Range― - ―
52-Week RangeCHF0.85 - CHF4.85
Previous CloseN/A
Volume178.76K
Average Volume (3M)2.48M
Market Cap
CHF791.95M
Enterprise ValueCHF1.82B
Total Cash (Recent Filing)CHF87.24M
Total Debt (Recent Filing)CHF1.27B
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Apr 28, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding252,461,100
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside50.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.48
Revenue Forecast (FY)CHF226.37M
Bulls Say, Bears Say
Bulls Say
Clinical Development And Regulatory PathwayA regulatory‑agreed Phase 3 program for lucerastat using kidney biopsy as primary evidence establishes a clear pathway to demonstrate kidney benefit and could enable an oral treatment option for a broad set of Fabry patients if trials are successful.
Corporate Governance And LeadershipReturn of Jean‑Paul Clozel to operational leadership together with plans to add independent directors signal a strategic shift toward prioritizing revenue growth and stronger governance that could improve execution and investor confidence.
Global Commercialization And LicensingExclusive distribution agreements across the Middle East and Latin America for daridorexant expand commercial reach and create milestone, supply, and royalty revenue streams that can strengthen near‑term cash and reduce the need for additional financing.
Bears Say
Financial Guidance And Expense PressureDeclining guidance visibility combined with rising operating expenses has led analysts to cut price targets, increasing the risk of funding shortfalls or the need for dilutive financing moves.
North American Partnering And Commercialization RiskAbsence of a confirmed North American partner for aprocitentan represents a material execution risk that could limit commercial uptake and reduce the drug's contribution to company value in a key market.
Regulatory And Trial Execution RiskApproval prospects depend heavily on proving meaningful kidney improvement in late‑stage studies, exposing valuation to significant downside if trials fail to meet regulators' required endpoints.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF0.85 and its highest was CHF4.85 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF791.95M.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Apr 28, 2026 which is in 35 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Feb 26, 2026. The company reported -CHF0.27 earnings per share for the quarter, missing the consensus estimate of -CHF0.195 by -CHF0.075.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.19.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 252,461,100 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.27 in its last earnings report, missing expectations of -CHF0.195. Following the earnings report the stock price went up 5.333%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF4.75
▲(50.79% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---